Q&A With Peter Traber From Galectin Therapeutics: Developing New Treatments For Fibrosis and Cirrhosis

In the effort to help the growing number of people with liver disease new medications are constantly being developed. This is true for a wide range of conditions including cirrhosis and fibrosis.

While not presenting any new data at this year's Liver Meeting in San Francisco Galectin Therapeutics CEO Peter Traber, MD, discussed work being done in this field which could provide much needed treatment for these patients in the near future.